Increased prefrontal cortical D1 receptors in drug naïve patients with schizophrenia: A PET study with [11C]NNC112

Journal of Psychopharmacology

Volumn 26, Issue 6, 2012, Pages 794-805

  Abi Dargham, Anissa ^a   Xu, Xiaoyan ^a   Thompson, Judy L ^a   Gil, Roberto ^a   Kegeles, Lawrence S ^a   Urban, Nina ^a   Narendran, Raj ^b   Hwang, Dah Ren ^c   Laruelle, Marc ^a,d,e   Slifstein, Mark ^a  

^a Unit 31 ^*  (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c AMGEN INC   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotics; D1 receptor; dorsolateral prefrontal cortex; positron emission tomography; schizophrenia

Indexed keywords

5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; CARBON 11; DOPAMINE 1 RECEPTOR; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; FEMALE; GENOTYPE; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE DISTRIBUTION; RECEPTOR BINDING; RECEPTOR UPREGULATION; SCHIZOPHRENIA; SOCIAL STATUS;

ADULT; ANTIPSYCHOTIC AGENTS; BENZAZEPINES; BENZOFURANS; DOPAMINE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D1; SCHIZOPHRENIA; UP-REGULATION;

EID: 84862148851     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111409265     Document Type: Article

References (80)

1. Abi-Dargham A, Gandelman M, Zoghbi SS, et al. Reproducibility of SPECT measurement of benzodiazepine receptors in human brain with iodine-123- iomazenil. J Nucl Med. 1995 ; 36: 167-175
2. Abi-Dargham A, Martinez D, Mawlawi O, et al. Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab. 2000 ; 20: 225-243
3. Abi-Dargham A, Mawlawi O, Lombardo I, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci. 2002 ; 22: 3708-3719
4. Akil M, Lewis DA. The cathecolaminergic innervation of the human entorhinal cortex: comparisons of schizophrenics and controls. Schizophrenia Res. 1995 ; 15: S25
5. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association ; 1994 :
6. Arnsten AF, Cai JX, Murphy BL, et al. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology. 1994 ; 116: 143-151
7. Arnt J, Hyttel J, Sanchez C. Partial and full dopamine D1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. EurJ Pharmacol. 1992 ; 213: 259-267
8. Arora RC, Meltzer HY. Serotonin2 (5-HT2) receptor binding in frontal cortex of schizophrenic patients. J Neural Transm. 1991 ; 85: 19-29
9. Bennett JP, Enna SJ, Bylund DB, et al. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry. 1979 ; 36: 927-934
10. Burnet PW, Eastwood SL, Harrison PJ. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 1996 ; 15: 442-455
11. Cai JX, Arnsten AFT. Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J Pharmacol Exp Ther. 1997 ; 283: 183-189
12. Cohen JD, Forman SD, Braver TS, et al. Activation of the prefrontal cortex in a nonspatial working memory task with functional MRI. Hum Brain Mapping. 1994 ; 1: 293-304
13. Daniel DG, Berman KF, Weinberger DR. The effect of apomorphine on regional cerebral blood flow in schizophrenia. J Neuropsychiatry Clin Neurosci. 1989 ; 1: 377-384
14. Daniel DG, Weinberger DR, Jones DW, et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci. 1991 ; 11: 1907-1917
15. Dean B, Hayes W. Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophrenia Res. 1996 ; 21: 133-139
16. Ekelund J, Slifstein M, Narendran R, et al. In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol. 2007 ; 9: 117-125
17. Erritzoe D, Rasmussen H, Kristiansen KT, et al. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients. Neuropsychopharmacology. 2008 ; 33: 2435-2441
18. Friston KJ, Holmes AP, Worsley KJ, et al. Statistical parametric maps in functional imaging: A general linear approach. Hum Brain Mapping. 1995 ; 2: 189-210
19. Gandelman MS, Baldwin RM, Zoghbi SS, et al. Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers: β-CIT, IBF and iomazenil. J Pharmac Sci. 1994 ; 83: 1014-1019
20. Gessa GL, Devoto P, Diana M, et al. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology. 2000 ; 22: 642-649
21. Goldman-Rakic PS, Muly EC, Williams GV. D(1) receptors in prefrontal cells and circuits. Brain Res Rev. 2000 ; 31: 295-301
22. Gonzalez-Maeso J, Ang RL, Yuen T, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature. 2008 ; 452: 93-97
23. Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull. 2001 ; 56: 441-451
24. Green MF, Marshall BD, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. Am J Psychiatry. 1997 ; 154: 799-804
25. Guo N, Hwang DR, Lo ES, et al. Dopamine depletion and in vivo binding of PET D1 receptor radioligands: implications for imaging studies in schizophrenia. Neuropsychopharmacology. 2003 ; 28: 1703-1711
26. Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: A postmortem study. Biol Psychiatry. 1997 ; 42: 529-545
27. Hall H, Sedvall G, Magnusson O, et al. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology. 1994 ; 11: 245-256
28. Halldin C, Foged C, Chou YH, et al. Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. J Nucl Med. 1998 ; 39: 2061-2068
29. Hirvonen J, van Erp TG, Huttunen J, et al. Brain dopamine d1 receptors in twins discordant for schizophrenia. Am J Psychiatry. 2006 ; 163: 1747-1753
30. Hollingshead AB Four Factor Index of Social Status. New Haven, CN: Working paper published by the author ; 1975 :
31. Ichikawa J, Ishii H, Bonaccorso S, et al. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001 ; 76: 1521-1531
32. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007 ; 27: 1533-1539
33. Joyce JN, Shane A, Lexow N, et al. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 1993 ; 8: 315-336
34. Karlsson P, Farde L, Halldin C, et al. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry. 2002 ; 159: 761-767
35. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987 ; 13: 261-276
36. Kern RS, Green MF, Marshall BD, et al. Risperidone versus haloperidol on secondary memory: can newer medications aid learning?. Schizophr Bull. 1999 ; 25: 223-232
37. Laruelle M, Abi-Dargham A, Casanova MF, et al. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: a postmortem study. Arch Gen Psychiatry. 1993 ; 50: 810-818
38. Lewis R, Kapur S, Jones C, et al. PET study of 5-HT2 receptors density in schizophrenia. Biol Psychiatry. 1999 ; 41: 63S
39. Lidow MS, Elsworth JD, GoldmanRakic PS. Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J Pharmacol Exp Ther. 1997 ; 281: 597-603
40. Lidow MS, Goldman-Rakic PS. A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci USA. 1994 ; 91: 4353-4356
41. Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005 ; 62: 361-370
42. Martinez D, Slifstein M, Broft A, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab. 2003 ; 23: 285-300
43. Matsumoto I, Inoue Y, Iwazaki T, et al. 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study. Neurosci Lett. 2005 ; 379: 164-168
44. Mawlawi O, Martinez D, Slifstein M, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D-2 receptor parameter measurements in ventral striatum. J Cerebr Blood Flow Metab. 2001 ; 21: 1034-1057
45. McGurk SR. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry. 1999 ; 60 (Suppl 12). 24-29
46. Melis M, Diana M, Gessa GL. Clozapine potently stimulates mesocortical dopamine neurons. Eur J Pharmacol. 1999 ; 366: R11-13
47. Meltzer CC, Zubieta JK, Links JM, et al. MR-based correction of brain PET measurements for heterogeneous gray matter radioactivity distribution. J Cereb Blood Flow Metab. 1996 ; 16: 650-658
48. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999 ; 25: 233-255
49. Memo M, Pizzi M, Missale C, et al. Modification of the function of D1 and D2 dopamine receptors in striatum and nucleus accumbens of rats chronically treated with haloperidol. Neuropharmacology. 1987a ; 26: 477-480
50. Memo M, Pizzi M, Nisoli E, et al. Repeated administration of (-)sulpiride and SCH 23390 differentially up-regulate D-1 and D-2 dopamine receptor function in rat mesostriatal areas but not in cortical-limbic brain regions. Eur J Pharmacol. 1987b ; 138: 45-51
51. Mita T, Hanada S, Nishino N, et al. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry. 1986 ; 21: 1407-1414
52. Murphy BL, Arnsten AF, Goldman-Rakic PS, et al. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Natl Acad Sci USA. 1996a ; 93: 1325-1329
53. Murphy BL, Arnsten AF, Jentsch JD, et al. Dopamine and spatial working memory in rats and monkeys: pharmacological reversal of stress-induced impairment. J Neurosci. 1996b ; 16: 7768-7775
54. Narendran R, Frankle WG, Keefe RS, et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry. 2005 ; 162: 2352-2359
55. Ngan ET, Yatham LN, Ruth TJ, et al. Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: A PET study using [(18)F]setoperone. Am J Psychiatry. 2000 ; 157: 1016-1018
56. Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 1997 ; 385: 634-636
57. Okubo Y, Suhara T, Suzuki K, et al. Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci. 2000 ; 66: 2455-2464
58. Pehek EA, Yamamoto BK. Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J Neurochem. 1994 ; 63: 2118-2124
59. Porceddu ML, Ongini E, Biggio G. [3H]SCH 23390 binding sites increase after chronic blockade of D-1 dopamine receptors. Eur J Pharmacol. 1985 ; 118: 367-370
60. Pralong D, Tomaskovic-Crook E, Opeskin K, et al. Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia. Schizophr Res. 2000 ; 44: 35-45
61. Rajarethinam R, Upadhyaya A, Tsou P, et al. Caudate volume in offspring of patients with schizophrenia. Br J Psychiatry. 2007 ; 191: 258-259
62. Rasmussen H, Erritzoe D, Andersen R, et al. Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 2010 ; 67: 9-16
63. Reynolds GP, Rossor MN, Ivesen LL. Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm. 1983 ;: 273-277
64. Rollema H, Lu Y, Schmidt AW, et al. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol. 1997 ; 338: R3-5
65. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998 ; 39: 904-911
66. Sawaguchi T, Goldman-Rakic PS. The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol. 1994 ; 71: 515-528
67. Seamans JK, Gorelova N, Durstewitz D, et al. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J Neurosci. 2001 ; 21: 3628-3638
68. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol. 2004 ; 74: 1-58
69. Slifstein M, Kegeles LS, Gonzales R, et al. [11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT(2A) receptors: a PET study in healthy human subjects. J Cereb Blood Flow Metab. 2007 ; 27: 1733-1741
70. Slifstein M, Kolachana B, Simpson EH, et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [(11)C]NNC112 and PET. Mol Psychiatry. 2008 ; 13: 821-827
71. Trichard C, Paillere-Martinot ML, Attar-Levy D, et al. No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr Res. 1998 ; 31: 13-17
72. Wang HD, Deutch AY. Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment. Neuropsychopharmacology. 2008 ; 33: 1276-1286
73. Watanabe M, Kodama T, Hikosaka K. Increase of extracellular dopamine in primate prefrontal cortex during a working memory task. J Neurophysiol. 1997 ; 78: 2795-2798
74. Westerink BH, Kawahara Y, De Boer P, et al. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol. 2001 ; 412: 127-138
75. Whitaker PM, Crow TJ, Ferrier IN. Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry. 1981 ; 38: 278-280
76. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 1995 ; 376: 572-575
77. Wright IC, Rabe-Hesketh S, Woodruff PW, et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. 2000 ; 157: 16-25
78. Yamamoto BK, Cooperman MA. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci. 1994 ; 14: 4159-4166
79. Youngren KD, Inglis FM, Pivirotto PJ, et al. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology. 1999 ; 20: 403-412
80. Zahrt J, Taylor JR, Mathew RG, et al. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci. 1997 ; 17: 8528-8535